May 03, 2019
Oxford BioDynamics Joins ALS Biomarker Study Sponsored By Mitsubishi Tanabe Pharma America
May 02, 2019
Post-Hoc Analyses of RADICAVA® (edaravone) Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency
Apr 11, 2019
Mitsubishi Tanabe Pharma America to Highlight ALS Research Initiatives at 2019 MDA Clinical & Scientific Conference
Mar 01, 2019
Mitsubishi Tanabe Pharma America Appoints Sam Shum as Vice President of Operations and Strategy
Feb 06, 2019
Mitsubishi Tanabe Pharma America Announces More Than 3,500 ALS Patients In The U.S. Have Been Treated With RADICAVA® (edaravone)
Jan 31, 2019
MTPA Launches National Online Directory Of ALS Specialists And Neurologists At Multidisciplinary Centers
Nov 28, 2018
Mitsubishi Tanabe Pharma America To Showcase ALS Research At 29th International Symposium On ALS/MND In Glasgow
Nov 15, 2018
Mitsubishi Tanabe Pharma Group Companies To Present New Data On Investigational Oral Formulation Of Edaravone For ALS At 29th International Symposium On ALS/MND
Sep 24, 2018
Mitsubishi Tanabe Pharma America Appoints Joseph Scalia as Vice President of Sales and Marketing
Jun 21, 2018
Mitsubishi Tanabe Pharma America to Present Data on RADICAVA® (edaravone) at the European Network for the Cure of ALS (ENCALS) Annual Meeting
Apr 18, 2018
Mitsubishi Tanabe Pharma America Announces ALS Presentations At American Academy Of Neurology Annual Meeting
Dec 05, 2017
Mitsubishi Tanabe Pharma America to Present Data on RADICAVA® (Edaravone) At 28th International Symposium on ALS/MND in Boston
Nov 30, 2017
Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA® (edaravone) to U.S. Department of Veterans Affairs National Formulary
Nov 21, 2017
Mitsubishi Tanabe Pharma America Expands Executive Leadership Team, Names Kevin O'Brien as Vice President of Market Access
Nov 16, 2017
Mitsubishi Tanabe Pharma America Announces 1,000 People with ALS Have Received FDA-Approved Treatment Option in First Three Months Available
Sep 07, 2017
Comprehensive Edaravone Clinical Program Data Published as Supplement to Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Journal
Sep 06, 2017
Mitsubishi Tanabe Pharma America Signs Agreement with Option Care For National Home Infusion Services
Aug 08, 2017
First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S.
Aug 01, 2017
MT Pharma America Announces Corporate Name Change to Mitsubishi Tanabe Pharma America